PPH — VanEck Pharmaceutical ETF
Data updated: 2026-08-26
PPH — VanEck Pharmaceutical ETF. Global (incl. US) Large Cap Blend / Core Health Care Equity · $879.46M AUM. Holdings, fees, performance and SEC filings.
PPH Fund Overview
PPH — VanEck Pharmaceutical ETF is a US ETF managed by VanEck ETF Trust, categorised as Global (incl. US) Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: VanEck ETF Trust
- Category: Global (incl. US) Large Cap Blend / Core Health Care Equity
- Assets under management: $879.46M
- 1-year return: 27.1%
- Ticker: PPH
- SEC CIK: 0001137360
- SEC series ID: S000034409
- Share class ID: C000105867
PPH Holdings
Top 10 holdings of VanEck Pharmaceutical ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co | 20.23% |
| Novartis AG | 10.63% |
| Merck & Co Inc | 9.85% |
| Novo Nordisk A/S | 5.37% |
| AbbVie Inc | 4.57% |
| Pfizer Inc | 4.51% |
| Bristol-Myers Squibb Co | 4.47% |
| Gsk PLC | 4.42% |
| Johnson & Johnson | 4.35% |
| AstraZeneca PLC | 4.33% |
PPH Portfolio Allocation
Asset-class allocation of VanEck Pharmaceutical ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.5% |
| Cash & Equivalents | 0.3% |
PPH Performance
Total returns for PPH (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.0% |
| 1 year | 27.1% |
| 3 years (annualised) | 13.8% |
| 5 years (annualised) | 10.5% |
PPH Risk Information
Risk metrics for PPH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.8%
PPH Costs and Fees
PPH costs about $36 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.36%
- Gross expense ratio: 0.36%
- Portfolio turnover: 30%
- Brokerage commissions: 1.67 bps of average net assets (SEC N-CEN)
PPH Cashflows
Over the 12 months to 2026-06, VanEck Pharmaceutical ETF had net inflows of $71.55M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$101.63M |
| 2026-05 | −$50.60M |
| 2026-04 | −$296.61M |
| 2026-03 | $64.96M |
| 2026-02 | $77.99M |
| 2026-01 | −$141.24M |
PPH Debt Constituents
No individual debt constituents are reported in VanEck Pharmaceutical ETF's latest SEC N-PORT filing.
PPH Prospectus and SEC Filings
Official VanEck Pharmaceutical ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-01-27
- Prospectus (485BPOS) — filed 2025-01-27
- Prospectus (485BPOS) — filed 2024-01-26
- Portfolio holdings (N-PORT) — filed 2026-08-26
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2025-12-09
- Annual census (N-CEN) — filed 2024-12-12
Related Funds
Other Global (incl. US) Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.